MFN Deadline Is Here: How Pharma Teams Can Respond Strategically

𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗹𝗲𝗿𝘁: 𝗠𝗙𝗡 𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝗜𝘀 𝗛𝗲𝗿𝗲. 𝗜𝘀 𝗬𝗼𝘂𝗿 𝗧𝗲𝗮𝗺 𝗥𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗪𝗵𝗮𝘁 𝗖𝗼𝗺𝗲𝘀 𝗡𝗲𝘅𝘁?

June 11 marks the end of the voluntary compliance window under the Most-Favored-Nation (MFN) Executive Order. If your organization hasn’t finalized a pricing strategy, the time for preemptive planning is over. But it’s not too late to respond strategically. 𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝗻𝗼𝘄? While the next steps from regulators are not fully defined, the EO outlines potential enforcement actions, including: ▪️ 𝗗𝗿𝘂𝗴 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝘁𝗶𝗼𝗻 𝘂𝗻𝗱𝗲𝗿 𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝟴𝟬𝟰 ▪️ 𝗘𝘅𝗽𝗼𝗿𝘁 𝗽𝗼𝗹𝗶𝗰𝘆 𝗿𝗲𝘃𝗶𝗲𝘄𝘀 ▪️ 𝗔𝗻𝘁𝗶𝘁𝗿𝘂𝘀𝘁 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻𝘀 ▪️ 𝗘𝘃𝗲𝗻 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝗿𝗲𝘃𝗼𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 𝗧𝗵𝗶𝘀 𝗺𝗮𝗸𝗲𝘀 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝗮𝗴𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗽𝗮𝘆𝗲𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁 𝗺𝗼𝗿𝗲 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝘁𝗵𝗮𝗻 𝗲𝘃𝗲𝗿. 𝗛𝗲𝗿𝗲’𝘀 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂 𝗰𝗮𝗻 𝗱𝗼 𝘁𝗼𝗱𝗮𝘆: 𝟭. 𝗨𝘀𝗲 𝗠𝗔𝗩𝗔® to gather payer sentiment and validate price thresholds 𝟮. 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗘𝗹𝗮𝘀𝘁𝗶𝗰𝗶𝘁𝘆™ to test fallback scenarios and model pricing impacts 𝟯. 𝗨𝘀𝗲 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗥𝗢𝗜 to assess rebate tradeoffs and negotiation risks 𝟰. 𝗧𝗿𝗮𝗰𝗸 𝗴𝗹𝗼𝗯𝗮𝗹 𝗺𝗮𝗿𝗸𝗲𝘁 𝘀𝗵𝗶𝗳𝘁𝘀 𝘄𝗶𝘁𝗵 𝗦𝗖𝗢𝗥𝗘™ to stay one step ahead At eMAX Health, we’re helping pharma clients answer the hard questions quickly. Download our MFN Readiness Guide Contact us to set up a response strategy session.